53. Summers JF, Brodbelt DC, Forsythe PJ *et al.* The effectiveness of systemic antimicrobial treatment in canine superficial and deep pyoderma: a systematic review. Veterinary Dermatology 23:305-329, 2012.
54. Koch HJ, Peters S. Antimicrobial therapy in German shepherd dog pyoderma (GSP). An open clinical study. Veterinary dermatology 7:177-181, 1996.
55. Bailly S, Fay M, Roche Y *et al.* Effect of quinolones on tumor necrosis factor production by human monocytes. International Journal of Immunopharmacology 12:31-36, 1990.
56. Knoller J, Brom J, Schonfeld W. Influence of ciprofloxacin on leukotriene generation from various cells in vitro. Journal of Antimicrobial Chemoterapy 25:602-612, 1989.
57. Altreuther P: Safety and tolerance of enrofloxacin in dogs and cats. Proceedings 1st Int. Symposium on Baytril, Bonn, 1992, pp: 15-19.
58. Silley P, Stephan B, Greife HA *et al.* Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. Journal of Antimicrobial Chemotherapy 60:999-1003, 2007.
59. Brown SA. Fluoroquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics 19:1-14, 1996.
60. Ghaffari MS, Parsamehr R. The effects of intravenous ciprofloxacin on the electrocardiogram of healthy dogs. Veterinary Research Communications 33:987-990, 2009.
61. Traş B, Maden M, Baş AL *et al.* Investigation of biochemical and haematological side-effects of enrofloxacin in dogs. Journal of veterinary medicine series a physiology, pathology, clinical medicine 48:59-63, 2001.
62. Taconelli E, De Angelis G, Cataldo MA *et al.* Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. Journal antimicrobial chemotherapy 61:26-38, 2008.
63. Nseir S, DePompeo C, Soubrier S *et al.* First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Critical Care Medicine 33: 283-289, 2005.
64. Gortel K, Campbell KL, Kakoma I *et al.* Methicillin resistance among *Staphylococci* isolated from dogs. American Journal of Veterinary Research 60:1526-1530, 1999.
65. Waller A. The creation of a new monster: MRSA and MRSI - important emerging veterinary and zoonotic diseases. Veterinary Journal 169:315-6, 2005.
66. Jones RD, Kania SA, Rohorbach BW *et al.* Prevalence of oxacillin- and multidrug-resistant sthaphylococci in clinical samples from dogs: 1772 samples (2001-2005). Journal of American Veterinary Medical Association 230:221-227, 2007.
67. Hanselman BA, Kruth S, Weese JS. Methicillin-resistant staphylococcal colonization in dogs entering a veterinary teaching hospital. Veterinary Microbiology 126:277-281, 2008.
68. Vengust M, Anderson ME, Rousseau J *et al.* Methicillin-resistant staphylococcal colonization in clinically normal dogs and horses in the community. Letters in Applied Microbiology 43:602-666, 2006.
69. Loeffler A, Linek M, Moodley A *et al.* First report of multiresistant, mecA positive *Staphylococcus intermedius* in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Veterinary Dermatology 18:412-412, 2007.
70. Zubeir IE, Kanbar T, Alber J *et al.* Phenotypic and genotypic characteristics of methicillin/oxacillin-resistant *Staphylococcus intermedius* isolated from clinical specimens during routine veterinary microbiological examinations. Veterinary Microbiology 121:170-176, 2007.
71. Descloux S, Rossano A, Perreten V. Characterization of new staphylococcal cassette chromosome mec (SCCmec) and topoisomerase genes in fluoroquinolone and methicillin-resistant *Staphylococcus pseudintermedius*. Journal of Clinical Microbiology 46:1818-1823, 2008.
72. Schwarz S, Kadlec K, Strommenger B. Methicillin-resistant *Staphylococcus aureus* and *Staphylococcus pseudintermedius* detected in the BfT-GermVet monitoring programme 2004-2006 in Germany. The Journal of Antimicrobial Chemotherapy 61:282-285, 2008.
73. Van Duijkeren E, Houwers DJ, Schoormans A *et al.* Transmission of methicillin-resistant *Staphylococcus intermedius* between humans and animals. Veterinary Microbiology 128:213-215, 2008.
74. Ruscher C, Lübke-Becker A, Wleklinski CG *et al.* Prevalence of methicillin-resistant *Staphylococcus pseudintermedius* isolated from clinical samples of companion animals and equidaes. Veterinary Microbiology 136:197-201, 2009.
75. De Lucia M, Moodley A, Latronico F, *et al.* Prevalence of canine methicillin resistant *Staphylococcus pseudintermedius* in a veterinary diagnostic laboratory in Italy. Research in Veterinary Science 91:346-348, 2011.
76. Colao V, Greco MF, Ventrella G *et al.* Indagine online sull'uso degli antibiotici nella clinica degli animali da compagnia. Summa 7:1-9, 2013.
77. Nienhoff U, Kadlec K, Chaberney IF *et al.* Methicillin-resistant *Staphylococcus pseudintermedius* among dogs admitted to a small animal hospital. Veterinary Microbiology 150: 191-197, 2011.
78. Weese JS, Faires MC, Frank LA *et al.* Factors associated with methicillin-resistant versus methicillin-susceptible *Staphylococcus pseudintermidius* infection in dogs. Journal of the American Veterinary Medical Association 240: 1450-1455, 2012.
79. Van Vlaenderen I, Nautrup BP, Gasper SM. Estimation of the clinical and economic consequences of non-compliance with antimicrobial treatment of canine skin infections. Preventive Veterinary Medicine 99:201-210, 2011.
80. Morris DO, Rook KA, Shofer FS *et al.* Screening of *Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi* isolates obtained from small companion animals for antimicrobial resistance: a retrospective review of 749 isolates (2003-04). Veterinary Dermatology 17:332-337, 2006.

ESCLUSIVO PER IL VETERINARIO

SOTTO MASSIMA COPERTURA

contro i parassiti e i loro morsi

Metodo line-on

Vectra® 3D

(Dinotefuran - Piriproxifene - Permetrina)

Il più ampio spettro in una pipetta unica

- Elimina le pulci per 1 mese
- Controllo delle pulci immature per 2 mesi
- Repelle e uccide le zecche
- 1 mese di efficacia contro flebotomi, mosche e zanzare

Metodo spot-on

Vectra® Felis

(Dinotefuran - Piriproxifene)

NOVITÀ

Lo specialista delle pulci

- Uccide le pulci in 2 ore e per 1 mese
- Controllo delle pulci immature per 3 mesi

0.6 - 10 KG

Per maggiori informazioni consultare il foglietto illustrativo sul sito **www.ceva-italia.it**

Ceva Salute Animale S.p.A. Viale Colleoni, 15 - 20864 Agrate Brianza (MB) - Tel. 0396559.442 - **marketing.italy@ceva.com**